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ABSTRACT 
Hyperthyroidism is a very common endocrine disorder in both humans and cats. 
Radioactive iodine ablation therapy is considered the gold standard; however, the patient 
becomes a radiation source and poses a potential radiological risk to others. The 
regulations governing when the patient can be released differ between human medicine 
and veterinary medicine. A human patient can receive up to 33 mCi of I-131 and be 
discharged the same day; yet a feline patient can receive a dose as low as 2 mCi and require 
multiple days of hospitalization. This discrepancy has not been satisfactorily addressed; 
and overly restrictive release criteria can place a burden on the veterinary staff, the patient, 
and the pet owner. In this study, administered activities and exposure rates are measured 
for hyperthyroid cats undergoing treatment at Louisiana State University Veterinary 
Teaching Hospital to determine if current criteria are too restrictive for releasing cats to 
their owners. Additionally, radioassays are performed on the surface of the cat, its excreta, 
and its environment to characterize the potential exposures to the pet owners. Annual total 
effective dose equivalents for the pet owners are calculated using the NRC’s equation from 
NUREG-1556 Vol 9. The results of the assays show that minimal radioactivity is present. 
The results of the TEDE estimates indicate that the majority of cats can be released the 
same day of injection and that the resulting TEDE to the pet owner is unlikely to exceed 
100 mrem, suggesting that current release criteria are overly conservative. 
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CHAPTER 1. INTRODUCTION 
1.1. Iodine-131, Hyperthyroidism, and Radioactive Iodine Therapy 
Iodine-131 (I-131) is a radioisotope of iodine with a physical half-life of 8.02 days; 
its primary decay emissions include a 606 keV β- particle with 89.6% abundance and a 364 
keV γ-ray with 81.5% abundance (Knolls Atomic Power Lab 2010). I-131 is normally a 
health concern after the release of fission products during a nuclear accident, as most 
recently following the Fukushima Daiichi incident (Tokonami et al., 2012). I-131 emits 
energetic γ-rays that pose an external exposure hazard while the β- particles can cause 
internal exposures if inhaled or ingested. I-131’s preferential uptake in the thyroid along 
with its biological half-life of 80 days in humans can irradiate the thyroid cells and 
potentially lead to thyroid cancer. However, the same properties that make I-131 a health 
concern also make it a valuable medical treatment. Any form of iodine that enters the body 
subsequently enters the blood stream as iodide. Once in the blood, iodide is actively 
transported from the blood into the thyroid’s functional unit, the follicle (Leggett, 2010). 
The iodide is concentrated into the follicle’s lumen where it is oxidized into iodine and 
incorporated into the protein thyroglobulin. Iodinated thyroglobulin is then moved back 
into the follicle cell and broken down into the thyroid hormones thyroxine (T4) and 
triiodothyronine (T3). After the thyroid hormones are secreted and broken down, iodine is 
eventually eliminated through the kidneys and urine, primarily, but also through saliva, 
feces, and sweat to a lesser extent. Medical professionals can use iodine’s biological role to 
treat thyroid disorders, most commonly hyperthyroidism.  
Hyperthyroidism is an common endocrinopathy characterized by an overactive 
thyroid and excessive production of T3 and T4 hormones (Ross, 2011).  Hyperthyroidism, 
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however, is not exclusive to humans and also afflicts cats. In fact, hyperthyroidism is the 
most commonly diagnosed endocrinopathy in older felines (Peterson, 2006). While the 
underlying cause of feline hyperthyroidism is not definitively known, benign, adenomatous 
hyperplasia—an increased reproduction rate of non-cancerous thyroid cells—is the most 
common diagnosis (Peterson, 2012). The clinical signs for a cat with hyperthyroidism most 
commonly include weight-loss, increased appetite, and increased drinking and urination 
due to the role that the T3 and T4 hormones play in metabolism (Peterson et al., 2016).  
The therapeutic options for feline hyperthyroidism are antithyroid medications, 
thyroidectomy, radioactive iodine ablation (RIA) treatment, and dietary therapy. 
Antithyroid medications require multiple daily administrations which can be difficult to do 
with feline patients. Even if the pill can be administered, some cats may not tolerate the 
side effects associated with the medication (Peterson, 2006). Most importantly, antithyroid 
medications are not curative. Dietary therapy is also non-curative, and the cat must 
maintain a strict iodine-deficient diet. Dietary therapy can also be difficult due to the 
dependence on the palatability of the low iodine food by the patient. Thyroidectomies, on 
the other hand, are a curative treatment option when successful. However, thyroidectomy 
carries the risks and complications associated with surgery and anesthesia (Peterson, 
2006). Though they can be curative, thyroidectomies can also result in failure to remove all 
the hyperplastic tissue resulting in relapse.   
Out of the available treatment options, RIA therapy is considered the treatment of 
choice by veterinarians (Carney et al., 2016). RIA is an effective and curative treatment for 
feline hyperthyroidism with a majority (≥95%) of cases resolved with a single dose; RIA is 
considered safe with minimal side effects and no associated mortality (Carney et al., 2016). 
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RIA’s efficacy is due to I-131’s physical and biological characteristics. The hyperplastic 
thyroid tissue is hyperfunctional; therefore, the radioactive iodine becomes concentrated 
there. The β- particles deposit their energy locally resulting in the ablation of those 
hyperplastic tissues while sparing healthy nearby tissues (Carney et al., 2016). RIA has a 
high cost up front, but the biggest disadvantage to RIA is the mandatory hospitalization 
period following treatment which can last from 3 days to 4 weeks depending on the 
administered dose and the regional regulations (Carney et al., 2016; Peterson, 2006). This 
disadvantage to RIA is unique to treatment of feline hyperthyroidism and is not present in 
treating human hyperthyroidism.  
1.2. Iodine-131 Release Criteria 
In human medicine, the patient release criteria for I-131 treatments are regulated 
by 10 CFR 35.75 which establishes an annual total effective dose equivalent (TEDE) limit of 
500 mrem to any individual and a 100 mrem limit above which instructions to maintain 
doses to others as low as reasonably achievable (ALARA) are required to be provided to the 
patient (CFR 2019b). NUREG-1556 Vol. 9 Rev. 2 provides guidance to medical use license 
holders including an equation to calculate TEDE and tables with activities and dose rates 
that are compliant with the 500 mrem and 100 mrem limits (NRC 2008). Table 1.1. 
summarizes the default release criteria for I-131. If a patient is administered an activity of 
33 mCi or less, hospitalization is not required. If a patient is administered an activity 
greater than 7 mCi, the patient must be given radiation safety instructions. Alternatively, if 
the patient has a measured dose rate less than 7 mrem/hr hospitalization is not required; 
and instructions must be given for measured dose rates above 2 mrem/hr.  
4 
 
Table 1.1. Summary of default release criteria for I-131 
TEDE Limit 
[mrem] 
Activity 
[mCi] 
Dose Rate 
[mrem/hr] 
500 33 7 
100 7 2 
Adapted from NU-REG 1556 Vol 9 Rev 2 
In veterinary medicine, the patient release criteria are regulated by 10 CFR 20.1301 
which establishes an annual TEDE limit of 100 mrem and a limit of 2 mrem in any hour in 
any unrestricted area (CFR 2019a).  NCRP 148 recommends a release criterion of 0.5 
mR/hr at 1 meter; however, NUREG-1556 Vol. 7 Rev. 1, which provides guidance for 
academic and research license holders under which veterinary medicine falls, recommends 
more restrictive release criteria (NCRP 2004, NRC 2018). Its recommendation for release 
criteria is at least 4 days of hospitalization and a measured dose rate less than 0.25 mR/hr 
at 1 foot (approximately 0.023 mR/hr at 1 meter) (NRC 2018). Moreover, both sets of 
release criteria are factors more conservative than the 100 mrem release criteria (2 
mrem/hr) from NUREG-1556 Vol. 9. The reasoning behind using more restrictive release 
criteria has not been elucidated by the Nuclear Regulatory Commission (NRC). 
Furthermore, the standard administered activity in feline RIA is 4 mCi, which is nearly half 
the 7 mCi recommendation for exceeding 100mrem; and doses as low as 2 mCi have been 
proven effective in treating feline hyperthyroidism; yet these doses require hospitalization 
(Lucy et al., 2017). Meanwhile, doses used in treating human hyperthyroidism can range 
from 5 mCi to 30 mCi and require no hospitalization. (Ross, 2011; Sisson et al., 2011).  
1.3. Motivation and Aims 
 The discrepancy between the release criteria can lead to confusing interpretations 
of the radiation risk. For example, this difference suggests that a cat administered 2 mCi 
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poses a greater risk than a human administered 33 mCi. One could argue the feline patient 
is not aware of its status as a radiation source and, therefore, cannot minimize exposure to 
others; however, the pet owner can follow instructions to keep their annual TEDE ALARA. 
NCRP Report No. 155 and Commentary No. 11 state that family members “should be 
distinct from members of the public” and their TEDE limits “should not be as restrictive” 
because they are willing to accept their radiation burden in exchange for psychological 
benefits (NCRP 2006, NCRP 1995). In NUREG 1492, a regulatory analysis of patient release 
criteria, the NRC acknowledges not only the economic costs to the hospital and patient 
from restrictive release criteria but also the psychological benefits to the patient from less 
restrictive criteria (NRC 1997). Pet owners are likely to face similar costs and benefits. A 
recent survey found that the biggest concern for most pet owners when considering RIA 
therapy for their cat was the hospitalization length—followed by travel distance and 
financial cost (Boland et al., 2014). This same survey revealed that 82% of owners thought 
their cat would be unhappy during its hospitalization and 65% of owners would miss their 
cat (Boland et al., 2014). An important initial step in analyzing the costs and benefits of 
different release criteria for feline patients and their owners is the assessment of dose to 
the pet owner.  
The aim of this current study is to provide conservative TEDE estimates of the pet 
owner following their cat’s RIA therapy and characterize the potential exposures from the 
cat. A multitude of studies have already investigated the dose estimates to family members 
and members of the public, and they have been summarized in the Oak Ridge National Lab 
(ORNL) report pertaining to patient release (Dewji and Hertel, 2017). The report’s 
summary can be put simply: high doses or thyroid uptakes are typically associated with 
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failure to adhere to ALARA guidance. Additionally, numerous studies have been conducted 
to provide more accurate equations that use less assumptions and more patient-specific 
data or more realistic models (DeSantis and Chabot, 2001; Siegel et al., 2007; Willegaignon 
et al., 2007; Zanzonico et al., 2000). These equations typically provide less restrictive 
release criteria compared to the default values from NUREG-1556 Vol. 9. To provide 
conservative TEDE estimates, administered activities and exposure rates of feline patients 
were taken, along with other measurements to further characterize the radioactivity of the 
feline patient. Then, those measurements were used with an adapted version of the NRC’s 
default equation in NUREG-1556 Vol. 9 to calculate the TEDE to the pet owner. The decision 
to use the default equation was based on a few reasons. First, while a couple of studies have 
developed biokinetic models for I-131 in hyperthyroid cats, agreed upon values for uptake 
fractions and effective half-lives for thyroidal and extrathyroidal compartments that could 
be used in patient-specific models are not currently available for felines (Chen et al., 2018; 
Hays et al., 1988). Second, the NRC should theoretically accept these TEDE estimates as 
showing compliance with the regulations because they were derived using their own 
equation. Third, the NRC default equation contains various conservative assumptions; 
therefore, actual TEDEs should be lower than the estimated TEDEs if the assumptions hold. 
1.4. Conservative Assumptions in NRC Default Equation 
 The following assumptions that are found within the NRC’s equation allow for 
conservative estimates for the TEDE. The equation assumes the maximally exposed person 
receives the dose from total decay. The equation contains an implicit assumption that 1 
roentgen of exposure results in 1 mrem of TEDE. The equation uses the radiological half-
life of I-131 and does not consider any voiding or biological elimination. Lastly, the 
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equation assumes the radioactivity of the patient is an unattenuated point source. Various 
studies have demonstrated that the point source model overestimates dose from nuclear 
medicine therapy patients (de Carvalho et al., 2011; Siegel et al., 2002; Sparks et al., 1998; 
Yi et al., 2013). 
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CHAPTER 2. MATERIALS AND METHODS 
2.1. Radioactive Iodine Treatment at Louisiana Veterinary Teaching Hospital 
All data was collected in accordance with Louisiana State University (LSU) 
Institutional Animal Care and Use Committee protocol #19-012.  Data was collected using 
feline patients at the LSU Veterinary Teaching Hospital (LSUVTH) that underwent the I-131 
ablation procedure. To be included in this study, the cat must have had a diagnosis of 
hyperthyroidism. Additionally the following exclusion criteria were used to limit the 
factors affecting the patients’ iodine biokinetics: the cat could not have had a 
thyroidectomy, could not have had advance kidney disease, could not have been 
administered thyroid suppressing medication in the week prior to RIA treatment, and 
could not have had thyroid cancer.  
After the pet owner has decided on RIA treatment, the cat is typically admitted to 
the LSUVTH on a Monday. The cat is housed inside a 70cm x 70cm x 70cm kennel in the 
iodine quarantine room for the entire duration of its stay. During its hospitalization, the cat 
is checked on twice daily and provided with fresh water and food and clean litter. Figure 
2.1. shows a typical kennel set up.  
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Figure 2.1. Typical kennel set up for feline patient receiving RIA therapy. The cat is provided 
food water, and litter in a small tray. Additionally, the bottom of the kennel is lined with 
towels and absorbent urine pads. 
 
The procedure routinely takes three days followed by two days of hospitalization. 
On Monday, the cat undergoes a physical exam that involves palpation of the thyroid gland 
to identify the presence of any cervical mass and to assess the symmetry of the disorder. 
The next day, Tuesday, a technetium-99m (Tc-99m) scan is performed to confirm the 
diagnosis and aid in determining the dose of I-131. On Wednesday, the cat is administered 
the sodium iodide I-131 solution via intrascapular subcutaneous injection, see Figure 2.2. 
LSUVTH utilizes low dose RIA and typically prescribes doses ranging from 2 mCi to 3 mCi. 
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Figure 2.2. A cat receiving an intrascapular subcutaneous injection. 
Source: https://vcahospitals.com/know-your-pet/giving-injections-to-cats 
 
Following injection, a radiation survey of the room is performed in order to identify 
any potential contamination. The feline patient typically remains in quarantine until Friday 
when a survey of the cat is performed to determine if the 0.5 mR/hr at 1 m release criteria 
used by LSUVTH is satisfied. If the feline patient’s exposure rate is below the criteria, the 
cat is released back into owner custody that afternoon. If the exposure rate does not meet 
the criteria, the patient remains hospitalized until the reading falls below the criteria so 
that the cat can be safely released back to the owner. After the cat is released, the owner 
must follow radiation safety instructions to minimize their exposure. Figure 2.3. shows the 
instructions provided to pet owners. 
11 
 
  
Figure 2.3. Home care instructions given to pet owners following their cats’ RIA therapy. 
These instructions help keep the dose to the pet owner ALARA. 
 
2.2. Administered Activities and Exposure Rates 
 In this study, seven feline patient case studies were followed that spanned from 
February to May of 2019. One cat was subsequently removed from the study because a 
review of its medical history revealed that a thyroidectomy had been previously 
performed. Administered activities were calculated by measuring the syringe’s activity 
before and after patient injection using 
𝑄 = 𝐴𝑓 − 𝐴0    (Equation 2.1) 
where Q is the administered activity in mCi, Af is the activity in the syringe after injection, 
and A0 is the activity in the syringe before injection. The 108 cm exposure rate readings in 
mR/hr were taken immediately after injection (day 0) and repeated each subsequent day 
(day 1 and day 2) during their hospitalization using a Fluke 451B ion chamber survey 
meter with a closed beta slide, pictured in Figure 2.4. Feline patients were discharged on 
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day 2 in accordance with the regular veterinary practice if they met the release criteria and 
were not kept hospitalized for the purposes of this study as that would not be considered 
ethical.  
 
Figure 2.4. Fluke 451B ion chamber survey meter used to perform exposure rate 
measurements in units of mR/hr. 
 
 To consistently perform the survey readings and reduce variability from distance, 
the cats were placed in a pet carrier to limit their movements. Tape was used to mark the 
100±1cm distance from the front of the carrier. However, the cat thyroid was maximally 
located 8±2cm into the carrier from the front. Therefore, exposure rate readings were 
taken at 108±2cm. Exposure rates at one meter were then calculated using the inverse 
square law 
𝑋1 = 𝑋0
𝑑0
2
𝑑1
2   (Equation 2.2.) 
where X1 is the exposure rate at one meter, X0 is the measured exposure rate at 108 cm, d02 
is the distance of the measured exposure rate, 108 cm, and d12 is 100 cm. The inverse 
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square law was also used to calculate the distance at which the exposure rate increases to 2 
mR/hr 
𝑑2 = √
𝑋1𝑑1
2
𝑋2
   (Equation 2.3.) 
where d2 is the distance at which the exposure rate increases to 2 mR/hr, d1 is 100cm in 
distance, X1 is the one-meter exposure rate, and X2 is an exposure rate of 2 mR/hr. Figure 
2.5. shows this experimental set-up. Additionally, five readings were taken at each survey.  
The mean exposure rate measurements were then fitted to an exponential curve to obtain 
an effective half-life of I-131 for each patient. 
 
Figure 2.5. Experimental set-up for collection of exposure rate data. The distance between 
the blue tape is 100 ± 1 cm. 
 
2.3. TEDE Estimates 
 
TEDE estimates were calculated using administered activities and the exposure 
rates for each of the three days during the patient’s hospitalization. The TEDE to the pet 
owner from each cat was calculated using an equation adapted from equation U.2. in 
NUREG-1556 Vol. 9 Rev. 2 
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𝑇𝐸𝐷𝐸(∞) =
34.6Γ𝑄𝑇𝑃𝐸
𝑟2
    (Equation 2.4.) 
where TEDE is the estimated total effective dose equivalent in mrem from total decay, 34.6 
is the product of the 24hr/d conversion factor and the total integration of decay (1.44), Γ is 
0.22 
𝑚𝑅∙𝑚2
ℎ𝑟∙𝑚𝐶𝑖
 the specific gamma constant for I-131, Q is the administered activity in mCi, Tp is 
the physical half-life of 8.02 days, E is the occupancy factor, r is the distance in meters 
(2008). The TEDE was calculated using both the administered activities and the exposure 
rate measurements and using occupancy factors of both 0.25 and 1. NUREG 1556 Vol 9 uses 
an occupancy factor of 0.25 for radionuclides with half-lives greater than 1 day. In this 
study, an occupancy factor of 1 was also used to simulate a situation where the pet owner 
could feasibly be at home all day with the cat such as a retiree or someone who works from 
home. When calculating TEDE from exposure rates, the product ΓQ is replaced by the 1m 
exposure rates, X1. 
𝑇𝐸𝐷𝐸(∞) =
34.6𝑋1𝑇𝑃𝐸
𝑟2
   (Equation 2.5.) 
Implicit in both Equation 2.4. and Equation 2.5. is a 1 R=1 rem conversion factor. The 
committed effective dose equivalent estimates for the inhalation and ingestion pathways 
were calculated using equation B.3. from NUREG-1556 Vol. 9 Rev. 2.  
𝐶𝐸𝐷𝐸 = 𝑄 ∗ 10−5 ∗ 𝐷𝐶𝐹 ∗ 1000   (Equation 2.6.) 
where CEDE is the committed effective dose equivalent in mrem, Q is the administered 
activity in mCi, 10-5 is the NRC’s assumed fractional intake, DCF is the I-131 dose 
conversion factor from the EPA Federal Guidance Report No 11 for either inhalation or 
ingestion in rem/mCi, 1000 is for the conversion from rem to mrem (EPA 1988).  
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2.4. Excreted Activities 
 Urine and fecal samples were collected from the patients to measure the amount of 
radioactivity excreted. Urine samples were collected in the form of either urine-soaked 
litter or a urine-soaked pad. For simplicity, both forms will simply be referred to as urine 
samples. The urine and fecal samples were collected at each check-in, and the excreta were 
placed in rigid syringe packs for 12 mL syringes, pictured in Figure 2.6. The rigid syringe 
packs were initially used so that the samples’ activities could be easily measured using a 
Biodex Atomlab 100 dose calibrator, shown in Figure 2.7. However, the rigid syringe packs 
limited the amount of sample that could be measured at once; so they were replaced with 
16.5x14.9 cm2 sealable zipper polyethylene sandwich storage bags for later samples due to 
the large amount of excreta that some patients produced. Urine pad samples were only 
collected when the staff determined urine was present based on visual and tactile 
inspection. The contaminated portion of the pad was removed with scissors to then be 
measured in the dose calibrator. Excreta samples were measured three times, and samples 
were grouped into 24-hour bins starting from time of injection. The excreta samples were 
decay corrected to the time of injection and used to calculate the ratio of the excreted 
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activity to the injected activity and multiplied by 100 to obtain the percent excreted 
activity. 
  
(a)       (b) 
Figure 2.6. Containers used to measure the activity of the excreta in the dose calibrator (a) 
Rigid syringe pack for a 12 mL syringe (b) Sealable zippered polyethylene sandwich 
storage bag 
 
 
Figure 2.7. Biodex Atomlab 100 dose calibrator used to measure excreted activity.  
2.5. Surface Contamination 
 Wipe tests were performed on the feline patients to detect any removable 
contamination on the cats’ surfaces. A wipe test was performed on each patient before 
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injection and repeated once each day during its hospitalization. The methodology for the 
wipe tests was adapted from Chalmers et al, 2006. One wipe was used to survey from the 
dorsal midline at the base of the neck extending caudally to the base of the tail as well as 
laterally along the abdomen areas.  Another wipe was used to survey all the paws on both 
the dorsal and palmar/plantar surfaces. The wipes used were 1 in2 polystyrene wipes. The 
wipes were then measured using one-minute counting times in a Packard Cobra II Model 
5002 gamma counter (Figure 2.8.a) and, subsequently, in a Beckman Model LS 6000LL 
liquid scintillation counter (LSC) (Figure 2.8.b). The net count rates were then converted to 
activity using each detectors’ efficiency. Additionally, wipe tests were performed on the 
kennel interior, food bowl, and water bowl at the time of patient discharge. The wipe of the 
kennel interior covered the lower half of the three kennel walls along with the kennel floor. 
   
(a)       (b) 
Figure 2.8. (a) Packard Cobra II Model 5002 gamma counter used to detect the gamma 
activity present on the wipes. (b) Beckman Model LS 6000LL liquid scintillation counter 
used to detect activity from beta-minus radiation on the wipes.  
 
2.6. Counter Efficiencies 
 To determine the efficiency of the gamma counter and LSC, six samples were 
prepared with a known radioactivity of iodine-131. A sodium iodide I-131 solution of 4 
mCi/ml obtained by Cardinal Health was serially diluted to 0.1 µCi/µL. Two microliter 
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drops were added to six polystyrene wipes, resulting in an activity of 0.2 µCi on each wipe. 
Three wipes were used to determine the efficiency of the gamma counter, and three were 
used to determine the efficiency of the LSC.  The samples’ count rates were measured using 
five-minute counting times at weekly intervals for 8 weeks. The measured count rates of 
the three samples were averaged and then divided by the expected disintegrations per 
minute, calculated using the known activity, to determine the counter’s efficiency. 
 
19 
 
CHAPTER 3. RESULTS AND DISCUSSION 
3.1. Injected Activities and Exposure Rates 
 The cats were treated with activities of carrier free sodium iodide I-131 in the range 
of 1.62 to 2.54 mCi with an average administered activity of 2.14 mCi. Mean exposure rates 
at 1 meter ranged from 0.23 to 0.46 mR/hr on day 0, from 0.19 to 0.43 mR/hr on day 1, and 
from 0.13 to 0.38 mR/hr on day 2. The values of the administered activities and the mean 
exposure rates are tabulated in Table 3.1. All administered activities were well below the 
NRC’s calculated activity limit for exceeding 100 mrem TEDE of 7 mCi. Additionally, all 
mean exposure rates are well below the corresponding dose rate limit of 2 mrem/hr. These 
findings suggest that the TEDE to the pet owner should be well below 100 mrem if an 
occupancy factor of 0.25 at a distance of 100 cm are valid assumptions.  
Table 3.1. Administered activities and mean exposure rates at 1 meter.    
Exposure Rate [mR/hr] 
Cat Prescribed Activity 
[mCi] 
Administered 
Activity [mCi] 
Day 0 Day 1 Day 2 
1 2.25 1.79±0.06 0.24±0.02 0.20±0.02 0.14±0.01 
2 2.94 2.48±0.08 0.47±0.02 0.43±0.01 0.34±0.01 
3 2.25 1.62±0.05 0.28±0.04 0.22±0.01 0.21±0.01 
4 2.50 1.92±0.06 0.23±0.02 0.19±0.01 0.13±0.01 
5 3.00 2.46±0.08 0.43±0.02 0.41±0.01 0.38±0.01 
6 3.00 2.54±0.08 0.36±0.02 0.38±0.01 0.30±0.01 
The administered activity values are the difference in the measured activity of the syringe 
before and after patient injection. The exposure rate values are the calculated exposure 
rates for 1 meter based on the measured exposure rates at 108 cm. Values are reported as 
the mean value plus/minus their standard error. 
 
The distances at which the exposure rate increases to 2 mR/hr ranged from 0.34 to 
0.48m on day 0, 0.31 to 0.46m on day 1, and 0.25 to 0.44m on day 2. Instructions should be 
given to the pet owner warning against spending an appreciable amount of time at this 
distance or closer to the cat. These distances can be found in Table 3.2. Based on these 
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results, if a pet owner maintains a distance of at least half a meter, then they should likely 
not receive more than 2 mrem in any hour.  
Table 3.2. Distance[m] at which the exposure rate increases to 2mR/hr.  
2 mR/hr distance [m] 
Cat Day 0 Day 1 Day 2 
1 0.35±0.02 0.31±0.02 0.26±0.01 
2 0.48±0.01 0.46±0.01 0.41±0.01 
3 0.37±0.02 0.33±0.01 0.32±0.01 
4 0.34±0.02 0.31±0.01 0.25±0.01 
5 0.46±0.01 0.45±0.01 0.44±0.01 
6 0.43±0.01 0.44±0.01 0.39±0.01 
Values are reported as the expected value plus/minus its standard error. A pet owner 
standing this distance from their pet for 1 hour would be exposed to 2 mR.  
 
Figure 3.1. illustrates exposure rates over time. The exposure rates were fitted to an 
exponential curve to determine the effective half-life and, subsequently, to calculate the 
biological half-life. Effective half-lives ranged from 2.2 to 14 d and biological half-lives from 
-19 to 72 d. Those values are tabulated in Table 3.3. Cats 1, 2, and 4 have R2 values over 
0.90 indicating that the variation in the data is explained by an exponential model. 
Additionally, the effective half-lives of cats 1, 2, and 4 are in agreement with the current 
literature ranging from 2 to 4 days (Martin et al., 2015; Roberts et al., 2015). This 
agreement suggests that cats 1, 2, and 4 exhibit the expected feline biokinetics for iodine-
131. Meanwhile, cats 3, 5, and 6 have unexpected biokinetics for iodine. Cat 5 had a high R2 
value, however, its effective half-life of 14 days is longer than expected. Similarly, cats 3 and 
6 have longer than expected half-lives of 4.8 and 7.2 days, respectively. Cat 6’s low R2 value 
can be explained by its exposure rate increase from 0.36mR/hr on day 0 to 0.38 mR/hr on 
day 1, suggesting that cat 6 exhibits slow uptake. Effective half-lives less than or equal to 4 
days are ideal as that signifies the feline patient is eliminating the I-131 faster than the I-
131 decays, which would reduce the pet owners’ exposure when in the vicinity of the cat.  
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Figure 3.1. Semi-log plot of patients’ exposure rates at 1 meter over time. The exposure 
rates were fitted to an exponential curve. Error bars signify plus/minus standard error. 
 
Table 3.3. Effective half-lives and biological half-lives  
Cat TE [d] R2 TB [d] 
1 2.2 0.99 3.0 
2 3.6 0.95 6.5 
3 4.8 0.85 12 
4 2.1 0.99 2.8 
5 14 0.99 -19 
6 7.2 0.51 72 
Effective half-lives (TE) are listed in the second column with their respective coefficient of 
determination (R2) in the third column. The last column contains the biological half-lives 
(TB) calculated from the effective half-lives. 
 
3.2. TEDE Estimates 
 The calculated TEDEs based on administered activity are tabulated in Table 3.4., 
while TEDEs based on measured exposure rates are tabulated in Table 3.5. The TEDE 
estimates using administered activity ranged from 25 to 39 mrem and from 99 to 155 
mrem, for occupancy factors of 0.25 and 1, respectively. These estimates are also 
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represented graphically in Figure 3.2. As illustrated in Figure 3.2., the estimated TEDEs 
based on administered activity and an occupancy factor of 0.25 are well below the 100 
mrem limit. Based on these results, all feline patients could have been released the day of 
injection without exceeding the pet owner’s annual limit. This result is expected given that 
all the administered activities are less than the NRC’s limit of 7 mCi. In the case of an 
occupancy factor of 1, for pet owners who are able to stay home with their cat all day, the 
estimated TEDEs for all but cat 3 exceed the 100 mrem. Only cat 3 could have been released 
the day of injection. Equation 2.4. can be solved empirically for the administered activity. 
Using an occupancy factor of 1 and TEDE limit of 100 mrem, administered activities would 
have to be below 1.64 mCi to release the patient the same day as injection. While low doses 
have been demonstrated to successfully treat feline hyperthyroidism by Lucy et al, this 
restrictive activity criteria can be circumvented by using measured dose rates as the 
release criteria (Lucy et al., 2017). 
Table 3.4. TEDE estimates based on administered activity   
TEDE [mrem] 
Cat Injected Activity [mCi] E = 0.25 E = 1 
1 1.79±0.06 27±1 109±4 
2 2.48±0.08 38±1 152±5 
3 1.62±0.05 25±1 99±3 
4 1.92±0.06 29±1 117±4 
5 2.46±0.08 38±1 150±5 
6 2.54±0.08 39±1 155±5 
Values are reported as expected value plus/minus standard error. 
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Figure 3.2. TEDE estimates based on administered activity. Error bars indicate plus/minus 
one standard error.  
 
The TEDE estimates using exposure rates and 0.25 occupancy ranged from 16 to 32 
mrem, 13 to 30 mrem, and 9 to 27 mrem for days 0, 1 and 2, respectively, and are 
illustrated in Figure 3.3.a. Again, the TEDE estimates using an occupancy factor of 0.25 are 
well below the 100 mrem limit. This result is expected since all the measured exposure 
rates are below the NRC’s limit of 2 mrem/hr, again suggesting that all feline patients could 
have been released on day 0 without exceeding the pet owner’s annual limit. The TEDE 
estimates using exposure rates and an occupancy factor of 1 ranged from 65 to 130 mrem, 
52 to 120 mrem, and 36 to 107 mrem, for days 0, 1, and 2, respectively. These estimates are 
illustrated in Figure 3.3.b. Like Equation 2.4., Equation 2.5. can also be solved analytically. 
The dose rate that corresponds to a 100 mrem limit and occupancy factor of 1 is 0.36 
mrem/hr. And indeed, this is evident in the results. Four of the cats could have been 
released on day 0, while cats 2 and 5 were not suitable for release until day 2. These results 
show the advantage of dose-rate-based release criteria over activity-based release criteria. 
While using the activity-based release criteria with an occupancy factor of 1, none of the 
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cats could have been released on injection day. In contrast, the dose-rate-based criteria 
could have allowed 4 out of 6 cats to be released on injection day. Further support for the 
use of dose-rate-based criteria comes from a previous studies that failed to find a linear 
relationship between measured exposure rates and administered activity (Feeney et al., 
2003; Weichselbaum et al., 2003). Other studies have also established that the measured 
dose rate is typically less than the calculated dose rate due to patient specific parameters 
such as self-shielding and biokinetics (Siegel et al., 2002; Yi et al., 2013). Therefore, using 
measured dose rates for release criteria is recommended because the TEDE estimates 
provided are more realistic compared to those calculated using administered activities, 
while still maintaining the conservativism of the NRC’s equation.  
Table 3.5. TEDE estimates based on measured exposure rates   
TEDE [mrem]  
Exposure Rate [mR/hr] E = 0.25 E = 1 
Cat Day 0 Day 1 Day 2 Day 0 Day 1 Day 2 Day 0 Day 1 Day2 
1 0.24±0.02 0.20±0.02 0.14±0.01 17±2 14±2 10±1 68±7 55±7 39±3 
2 0.47±0.02 0.43±0.01 0.34±0.01 32±2 30±1 23±1 129±7 120±4 94±4 
3 0.28±0.04 0.22±0.01 0.21±0.01 19±2 15±1 14±1 78±10 61±3 58±3 
4 0.23±0.02 0.19±0.01 0.13±0.01 16±2 13±1 9±1 65±7 52±3 36±3 
5 0.43±0.02 0.41±0.01 0.38±0.01 30±2 28±1 27±1 120±7 113±4 107±4 
6 0.36±0.02 0.38±0.01 0.30±0.01 25±1 27±1 21±1 100±4 107±4 84±4 
Values are reported as expected value plus/minus uncertainty. 
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(a) 
  
(b) 
Figure 3.3. (a) TEDE estimates based on measured exposure rates using an occupancy 
factor of 0.25. Error bars indicate plus/minus one standard error. (b) TEDE estimates 
based on measured exposure rates using an occupancy factor of 1. Error bars indicate 
plus/minus one standard error. 
 
The CEDE estimates ranged from 0.53 to 0.84 mrem for the inhalation pathway and 
0.86 to 1.35 mrem for the ingestion. CEDE estimates for each pathway and their sums are 
tabulated in Table 3.6. NUREG-1556 Vol. 9. recommends neglecting CEDE if it makes up less 
than 10% of the TEDE. The CEDE is 5.6% for all cats and, therefore, can be ignored. The fact 
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that the CEDE was 5.6% of the TEDE for all cats is due to the fixed nature of the TEDE and 
CEDE equations used. When a ratio of CEDE to TEDE is calculated, the administered activity 
term Q cancels out, leaving a ratio of 0.056 which is independent of the administered 
activity. Given the already low doses administered to feline patients, these findings 
reinforce that the dose contribution from internal exposures is negligible especially 
compared to dose contributions from external exposures.  
Table 3.6. Committed Effective Dose Equivalent from inhalation and ingestion pathways   
CEDE [mrem] 
 
Cat Administered 
Activity [mCi] 
Inhalation Ingestion Cumulative %TEDE* 
1 1.79±0.06 0.59±0.02 0.95±0.03 1.54±0.04 5.6 
2 2.48±0.08 0.82±0.03 1.32±0.04 2.14±0.05 5.6 
3 1.62±0.05 0.53±0.02 0.86±0.03 1.39±0.03 5.6 
4 1.92±0.06 0.63±0.02 1.02±0.03 1.65±0.04 5.6 
5 2.46±0.08 0.81±0.03 1.30±0.04 2.11±0.05 5.6 
6 2.54±0.08 0.84±0.03 1.35±0.04 2.19±0.05 5.6 
Values are reported as the expected value plus/minus its standard error.  
*%TEDE calculated as the ratio of the CEDE estimates and TEDE estimates based on 
administered activities and an occupancy factor of 0.25 
 
3.3. Excreted Activities  
 The percent total excreted activity for the feline patients ranged from 1.09% to 
9.25% in the first 24-hours and from 2.32% to 16.54% in the second 24-hours. Table 3.7. 
lists the percent excreted activity for the urine-soaked litter, urine pads, feces, the total for 
each day, and the 48hr total. The total percent excreted after 48 hours ranged from 3.41% 
to 24.50% which is lower than results from previous studies that found at least 50% of 
activity excreted in the first 48 hours (Feeney et al., 2003; Lamb et al., 2013; Martin et al., 
2015).  
This part of the experiment was not without difficulties. Excrement samples were 
initially collected using rigid syringe packs (pictured in Figure 2.7.). Rigid syringe packs 
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were initially chosen because they allowed for easy measurement of the sample’s activity in 
the dose calibrator. However, the rigid syringe packs were deemed inefficient due to the 
restrictive sample amount that could be collected compared to the amount of excreted 
material to be analyzed. Starting with cat 4, the packs were replaced with polyethylene 
sandwich bags. The polyethylene sandwich bags allowed for greater amounts of excreta to 
be measured within the dose calibrator. Another difficulty was the inconsistent urine and 
feces production of the patients. Some patients did not produce feces within a given 24-hr 
period. On some occasions, the patients spilled contaminated litter outside of the tray. On 
others, patients would not contain their urine production within the litter tray although 
this loss was partly mitigated by the urine pads. Although the % activity excreted was 
lower than expected, % activity excreted in urine was higher than % activity excreted in 
feces for any given cat in either 24-hr period. This result is expected due to the fact that 
iodine clears out the body predominantly through the kidneys (Leggett, 2010).  
Table 3.7. Percent activity excreted 
Values are reported as the expected value plus/minus its uncertainty. 
*Urine-pad activity was measured if visual or tactile inspection indicated the presence of 
urine. 
** Some feline patients did not produce fecal samples throughout the 24-hour period.  
           
 
Cumulative Total
Cat Litter Pad Feces Total Litter Pad Feces Total
1 0.64±0.02 * 0.60±0.02 1.24±0.03 2.71±0.09 * ** 2.71±0.09 3.95±0.09
2 1.58±0.05 * ** 1.58±0.05 3.86±0.12 * ** 3.86±0.12 5.44±0.13
3 1.09±0.03 * ** 1.09±0.03 2.22±0.07 * 0.10±0.00 2.32±0.07 3.41±0.08
4 9.25±0.39 * 0.04±0.00 9.29±0.39 9.51±0.40 * ** 9.51±0.40 18.80±0.56
5 7.50±0.24 0.46±0.02 ** 7.96±0.24 8.04±0.26 5.05±0.16 3.45±0.11 16.54±0.32 24.50±0.40
6 4.17±0.13 * ** 4.17±0.13 4.27±0.14 * 1.48±0.05 5.75±0.15 9.92±0.20
% Activity Excreted
1st 24 hours 2nd 24 hours
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 3.4. Surface Contamination 
 The wipe tests done before injection were all within background, but wipes from 
day 1 and day 2 detected removable radioactivity on the surface of the patients. Figure 3.4. 
and Figure 3.5. show the surface activity from the gamma counter measurements and LSC 
measurements, respectively. Surface contamination on day 1 ranged from 0.16 to 0.52 nCi 
on the body and from 0.08 to 0.80 nCi on the paws based on the gamma counter and its 
efficiency. Surface contamination ranged from 0.20 to 0.46 nCi on the body and from 0.08 
to 0.73 nCi on the paws based on the LSC and its efficiency. The presence of removable 
contamination is expected given that iodine can be eliminated from the body through the 
salivary glands. When the patient grooms themselves, they deposit the radioactive iodine 
from the saliva onto their surface. However, cross-contamination from contaminated litter 
could potentially contribute to the removable contamination found on the surface of the 
patient, especially on the paws. Regardless of the source of the removable contamination, 
our data shows that the activities are below 1 nCi. Additionally, our data shows that Day 2 
activities were significantly lower than or equal to Day 1 activities, but never significantly 
higher.  
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Figure 3.4. Surface Activity on feline patient based on gamma counter measurements. 
The blue columns indicate the surface activity of the body, while gold columns indicate 
activity for the paws. Error bars indicate plus/minus one standard deviation. 
 
 
Figure 3.5. Surface activity on feline patient based on LSC measurements. The blue columns 
indicate the surface activity of the body, while gold columns indicate activity for the paws. 
Error bars indicate plus/minus one standard deviation.  
 
 Aside from the cat’s surface, any surface that could become contaminated and 
subsequently touched by the pet owner was of interest. Food and water bowls were 
assayed as well as the kennel interior. Activities on these other surfaces are shown in 
Figures 3.6. and 3.7. for the gamma counter and LSC, respectively. Activities on the kennel 
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interior ranged from 0.08 nCi to 4.84 nCi based on measurements from the gamma counter 
while they ranged from 0.07 nCi to 3.89 nCi based on LSC measurements. Activities on the 
food bowl and water bowl ranged from 0.01 nCi to 0.20 nCi and 0.03 nCi to 0.17 nCi, 
respectively, for the gamma counter. For the LS counter, activities on the food and water 
bowls ranged from 0.04 nCi to 0.19 nCi and 0.03 nCi to 0.14 nCi, respectively. The food and 
water bowls had negligible activities whereas the kennel interior had activities elevated 
above background. However, the reason for the elevated activities is unclear and is not 
present for all the patients. The little contamination present on the bowls was likely from 
any saliva transfer when the patient was eating and drinking. Contamination inside the 
kennel may be from the patient rubbing against the walls or floor; however, the activities 
on the surface of the cat were lower than those found on the kennel interior. The elevated 
activities could more likely be explained by urine contamination from improper use (or 
lack of use) of the litter tray.  
 
Figure 3.6. Contamination on other surfaces based on gamma counter measurements. Error 
bars indicate plus/minus one standard deviation.  
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Figure 3.7. Contamination on other surfaces based on LSC measurements. Error bars 
indicate plus/minus one standard deviation. 
 
3.5. Counter Efficiencies 
 Figures 3.8. and 3.9. show the measured count rates as a function of time along with 
their efficiencies for the gamma counter and LSC, respectively. As illustrated in Figure 3.8., 
the count rates obtained with the gamma counter are well fitted to an exponential curve. 
The same result is apparent in Figure 3.9. apart from the first data point. The explanation 
for this deviant data point is likely that the activity was saturating the LSC resulting in 
increased dead time, which would also explain why that data point has the lowest 
efficiency. For the gamma counter, an efficiency of 0.3 was used when calculating activities 
from the counting data. An efficiency of 0.3 was decided upon because the magnitudes of 
the measured count rates of the last data point are comparable to those measured on the 
surface of the patient. Following similar logic, an efficiency of 0.66 was used for 
determining activities using counting data from the LSC. 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
2 3 4 5 6
A
ct
iv
it
y 
[n
C
i]
Feline Patient 
Contamination on other surfaces based on LSC
Cage
Food Bowl
Water Bowl
32 
 
  
Figure 3.8. Count rates and efficiencies from gamma counter. Error bars indicate 
plus/minus one standard deviation. 
 
  
Figure 3.9. Count rates and efficiencies from LSC. Error bars indicate plus/minus one 
standard deviation.
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CHAPTER 4. CONCLUSIONS 
 
4.1. Key Findings 
The present study characterized several aspects of radiation exposure to the pet 
owner from their cat. Half of the cats had effective half-lives consistent with the literature 
of less than 4 days. Effective half-lives in this range are preferable because the radioactivity 
is eliminated so the exposure to the pet owner from the cat itself is reduced. Additionally, if 
the pet owner is greater than half a meter away, then the received dose should not exceed 2 
mrem in any hour for cats that were administered activities no greater than 2.54 mCi.  
The main elimination pathway of iodine in cats is through the urine as evidenced by 
the urine samples’ containing the highest amounts of radioactivity. Radioactivity was also 
found, though in smaller amounts, on the surface of the cat and its environment. This 
radioactivity is suspected to come from contamination from saliva, but urine contamination 
is also possible. Typically, surface contamination was present at levels below 1 nCi; 
however, some exceptions were found on the surface of the inside of the cage. The 
elimination pathway behind the elevated activity inside the cage is unknown but suspected 
to be from urine contamination.  
Aside from characterizing the sources of exposure, this study provides conservative 
estimates of TEDE to the pet owner following their cats’ RIA therapy. Using the NRC’s 
default equations, this study demonstrated that the CEDE is always less than 10% of the 
TEDE and can be neglected. With an occupancy factor of 0.25 at a distance of 100 cm, 
calculated TEDEs to the pet owners were well below the 100 mrem limit; and the feline 
patients could, in theory, have been safely sent home the day of injection with home care 
instructions for the owner. Even when using the more conservative occupancy factor of 1, 
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the majority of the patients could have been sent home the day of injection without the pet 
owners’ TEDE exceeding 100 mrem. These results coupled with the conservatism built into 
the equation suggest that the actual TEDE to the pet owner is not likely to exceed 100 
mrem for administered activities below 2.54 mCi assuming the pet owner does not 
blatantly disregard the home care instructions.  
4.2. Limitations 
This study had several limitations in its design, the first being its small sample size. 
A larger sample size would allow for more accurate generalizations to be drawn from the 
data and would reduce the effects of any possible outliers. One result of the small sample 
size is a limited administered activity range. The standard dose for treating feline 
hyperthyroidism is 4 mCi; LSUVTH prescribes a maximum of 3 mCi. The highest 
administered activity in the study is 2.54 mCi, meaning that our TEDE, effective half-life, 
excreted activity, and surface contamination data may not be applicable for administered 
activities above 2.54 mCi. In addition to small sample size, short collection time is another 
limitation. Data was only collected over the two days which is short compared to the 8-day 
physical half-life of I-131. Ideally, data would have been collected over a longer period of 
time; but patients could not have been held past when they met the release criteria for 
ethical reasons. Other limitations are the previously mentioned issues with collecting urine 
and feces samples. The container used to hold the samples and measure them in the dose 
calibrator was changed partway through the experiment. This change makes comparing 
samples across all patients difficult without knowing the affect the containers had on the 
measured activity in the dose calibrator. Additionally, some excreted activity was lost due 
to poor containment within the litter pan. Lastly, cat movement during exposure rate 
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measurements was a source of uncertainty. Though steps were taken to minimize this 
effect, feline patients did not necessarily stay still during data collection, causing 
fluctuations in the exposure rate readings.   
4.3. Future Work 
The conservative TEDE estimates presented here could provide the preliminary 
groundwork for analyzing the costs and benefits of less restrictive release criteria for feline 
patients. Another factor that should be addressed in detail are the economic costs on 
veterinary hospitals and pet owners when more restrictive release criteria are used. 
Moreover, the present study addresses TEDE estimates to the pet owner when they have 
one cat that receives RIA therapy. However, cats have relatively short lives compared to 
humans; therefore, a single pet owner can have multiple cats throughout their lifetime that 
receive RIA therapy. A single pet owner can also have multiple cats at the same point in 
time that require the treatment. These such circumstances should be considered in any 
future cost-benefit analysis 
Another aspect of feline patient release that should be addressed in depth in future 
studies is managing the cat’s biological waste. The activities present in the litter at the time 
of release would be high enough to set off radiation detectors at the local landfill. Pet 
owners are already given instructions to hold waste for 2 weeks so that the radiation 
decays away. However, no methodology has been presented to keep doses ALARA while 
handling and storing the waste.  
This study provides insight on the radioactive characteristics of a cat during 
hospitalization; repeating these measurements on a cat that is released to its owner the 
same day as injection would be interesting to see if any significant changes in the data 
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occur when the cat is in its home environment. Cats during hospitalization may be less 
likely to eat and drink, and therefore, less likely to urinate and defecate. Cats may not 
groom themselves as much when hospitalized. Conversely, they may groom excessively. 
Once at home a cat may not spend time in close contact with a contaminated litter box. All 
these factors can affect how the radioactivity is excreted from the cat and affect its 
potential to spread contamination.  
Moreover, TEDE estimates that account for patient attenuation, source geometry, 
fractional uptakes, and effective half-lives could further help illuminate whether feline 
release criteria are too restrictive. Measurements of pet owner thyroid burden after the cat 
has been home for some time could also provide insight into the TEDE received by pet 
owners.  
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